PegADA
PegADA Uses, Dosage, Side Effects, Food Interaction and all others data.
Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Used to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine, 2'-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
| Trade Name | PegADA |
| Availability | Discontinued |
| Generic | Pegademase |
| Pegademase Other Names | PEG-adenosine deaminase, pegADA, Pegademase, Pegademase bovine |
| Related Drugs | Adagen, Revcovi |
| Type | |
| Formula | C1821H2834N484O552S14 |
| Weight | 40788.2 Da |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
PegADA is a modified form of bovine adenosine deaminase used to treat adenosine deaminase deficiency, a condition which leads to the formation of adenosine metabolites which are cytotoxic to lymphocytes.
For treatment of adenosine deaminase deficiency
PegADA is also used to associated treatment for these conditions: Adenosine Deaminase Deficiency
How PegADA works
PegADA converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
PegADA Disease Interaction
Elimination Route
Time to peak for plasma adenosine deaminase is 2 to 3 days
Half Life
plasma adenosine deaminase elimination half-life is 3 to >6 days
Innovators Monograph
You find simplified version here PegADA
